Trials / Sponsors / wang shusen
wang shusen
Academic / Other · 6 registered clinical trials — 1 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy Breast Neoplasms | Phase 2 | 2023-09-20 |
| Suspended | Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negati Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer | Phase 2 | 2022-11-23 |
| Unknown | Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negati Breast Cancer | Phase 2 | 2022-10-03 |
| Unknown | Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label Triple Negative Breast Cancer | Phase 2 | 2022-08-01 |
| Unknown | PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line Chemotherapy Breast Cancer, Brain Metastasis | N/A | 2017-08-01 |
| Unknown | The Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia Breast Cancer | Phase 3 | 2016-05-04 |